Dynavax Technologies Corp. (DVAX) spiked to the downside in the early afternoon Friday after the FDA cancelled a meeting with the Vaccines and Related Biological Products Advisory Committee to assess Dynavax's Hepatitis B vaccine. The FDA stated that it cancelled the meeting to give the company time to "review and resolve several outstanding issues."
from RTT - Before the Bell http://ift.tt/2bPQCZN
via IFTTT
No comments:
Post a Comment